Company Overview of Bellicum Pharmaceuticals, Inc.
Bellicum Pharmaceuticals, Inc. operates as a biotherapeutics company that develops novel therapies for the treatment of cancer and other diseases. It offers AP1903, a lipid permeable and synthetic organic compound used in conjunction with a chemical induction of dimerization (CID) therapy; BPX-101, an autologous vaccine for the treatment of patients with metastatic castrate resistant prostate cancer and other cancers; and CaspaCIDe DLI (donor lymphocyte infusions), a self destruct switch used in the areas of stem cell therapy and hematopoietic stem cell transplantation. The company was founded in 2004 and is based in Houston, Texas.
6400 Fannin Street
Houston, TX 77046
Founded in 2004
Key Executives for Bellicum Pharmaceuticals, Inc.
Bellicum Pharmaceuticals, Inc. Key Developments
Similar Private Companies By Industry
|Natural Biosciences, Inc.||United States|
|Aeropharm Technology LLC||United States|
|Formula Pharmaceuticals, Inc.||United States|
|Health & Beyond Nutra Company Inc.||United States|
|BioRexis Pharmaceuticals Corporation||United States|
Recent Private Companies Transactions
August 22, 2014
To contact Bellicum Pharmaceuticals, Inc., please visit www.bellicum.com. Company data is provided by Capital IQ. Please use this form to report any data issues.